Antibody-Driven Dengue Severity: How IgG Shapes Dengue Risk
Official title: Mechanisms of Antibody-Dependent Enhancement of Dengue Disease
Funded at Rockefeller University · NIH-11397299 · Data updated 2026-11-12
This grant explores how certain dengue antibodies may make illness worse and what that means for vaccines and therapies.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Rockefeller University NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | September 24, 2018 |
| Project end | August 31, 2028 |
| Funding year | 2026 |
| Award (this year) | $459,711 |
| NIH project number | 5R01AI137276-09 |
| Project ID | NIH-11397299 on NIH RePORTER |
Who could benefit from this research
✓Could help
People at risk for dengue or those who have had dengue before and may participate in related future studies or trials.
✕Less likely to help
Individuals without dengue exposure or those not involved in any related studies may not benefit.
What this research studies
The project looks at how antibodies against dengue can sometimes help the virus infect immune cells, potentially making dengue disease more severe. It uses lab-based tests to study how antibody features, like specific sugar patterns, influence this process. By linking antibody characteristics to disease outcomes, the work aims to guide safer vaccines and effective treatments. The research is grounded in observations from dengue-endemic areas and builds on prior collaborations to understand human-relevant immune responses.
Why it matters
Potential benefit: If successful, the work could inform safer dengue vaccines and therapies by identifying antibody traits that increase protection rather than risk.
How similar studies have gone: Previous work has shown specific antibody features correlate with disease severity, suggesting this approach has translational potential.
Where this research is happening
-
Rockefeller University
New York, United States Active
Researchers
- Principal investigator: Bournazos, Stylianos — Rockefeller University
- Study coordinator: Bournazos, Stylianos
Related research
Other NIH-funded projects on the same topics.
-
Immune responses linked to severe dengue in children (primary infection)
This grant studies why some kids get very sick from their first dengue infection and how their immune system reacts differently from secondary infections.
-
Phase 2b trial of dengue vaccines TAK-003 and Butantan-DV to boost lasting, broad antibody protection
A trial tests whether giving a second dengue vaccine (Butantan-DV) after an initial TAK-003 shot can create stronger, longer-lasting antibodies that work against all dengue types.
-
Protective dengue vaccines that steer T and B cell responses
A vaccine study aims to guide the body’s T and B cells to fight all four dengue virus types safely and effectively.
-
Selective GAK inhibitors to fight dengue, VEEV and other emerging viral infections
A Stanford team is testing new, selective inhibitors of GAK to block how certain viruses enter and exit cells, with the goal of a broad antiviral approach that could help people exposed to dengue, VEEV, and similar infections.
-
Defining immune markers predicting protection against dengue in a long-term family study in Thailand
This grant looks at how antibodies develop to protect against dengue in children from a long-running family cohort in Thailand, with the goal of identifying immune signs that predict protection across multiple dengue serotypes.
-
Understanding dengue protection in children from a long-term Thai family cohort
A long-term study in Thailand follows families to understand how early exposures to dengue shape protection and illness risk for children as they encounter the virus over time.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.